PH12014501044B1 - Methods for improved wound closure employing olivamine and human umbilical vien endothelial cells - Google Patents

Methods for improved wound closure employing olivamine and human umbilical vien endothelial cells

Info

Publication number
PH12014501044B1
PH12014501044B1 PH12014501044A PH12014501044A PH12014501044B1 PH 12014501044 B1 PH12014501044 B1 PH 12014501044B1 PH 12014501044 A PH12014501044 A PH 12014501044A PH 12014501044 A PH12014501044 A PH 12014501044A PH 12014501044 B1 PH12014501044 B1 PH 12014501044B1
Authority
PH
Philippines
Prior art keywords
methods
olivamine
vien
endothelial cells
compositions
Prior art date
Application number
PH12014501044A
Other versions
PH12014501044A1 (en
Inventor
Darlene Mccord
Original Assignee
Mccord Darlene E
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/832,188 external-priority patent/US8796315B2/en
Application filed by Mccord Darlene E filed Critical Mccord Darlene E
Publication of PH12014501044A1 publication Critical patent/PH12014501044A1/en
Publication of PH12014501044B1 publication Critical patent/PH12014501044B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells

Abstract

The present disclosure relates to compositions for and methods of improving wound healing, including compositions for and methods of treating chronic wounds, and compositions for the inhibition and treatment of necrosis and extended quiescence that result in cellular necrosis instead of normal proliferation. The methods for wound healing administer one or more compositions including hydroxytyrosol and oleuropein with cells derived from umbilical cord blood.
PH12014501044A 2013-03-15 2014-05-08 Methods for improved wound closure employing olivamine and human umbilical vien endothelial cells PH12014501044B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/832,188 US8796315B2 (en) 2009-06-25 2013-03-15 Methods for improved wound closure employing olivamine and human umbilical vein endothelial cells
PCT/US2014/022490 WO2014150174A1 (en) 2013-03-15 2014-03-10 Methods for improved wound closure employing olivamine and human umbilical vein endothelial cells

Publications (2)

Publication Number Publication Date
PH12014501044A1 PH12014501044A1 (en) 2015-01-12
PH12014501044B1 true PH12014501044B1 (en) 2015-01-12

Family

ID=51580709

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12014501044A PH12014501044B1 (en) 2013-03-15 2014-05-08 Methods for improved wound closure employing olivamine and human umbilical vien endothelial cells

Country Status (2)

Country Link
PH (1) PH12014501044B1 (en)
WO (1) WO2014150174A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160354411A1 (en) * 2015-06-05 2016-12-08 Darlene E. McCord Olivamine-induced improvement in endothelial cells viability and function
US20190046547A1 (en) * 2016-02-08 2019-02-14 Hackensack University Medical Center Compositions and methods for treating chronic wounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6437004B1 (en) * 2000-04-06 2002-08-20 Nicholas V. Perricone Treatment of skin damage using olive oil polyphenols
NZ534884A (en) * 2002-02-13 2007-05-31 Creagri Inc Method and composition for treatment of inflammation and AIDS-associated neurological disorders
US20070207228A1 (en) * 2004-03-02 2007-09-06 Giammaria Giuliani Composition for Regulating the Trophism of Hair Follicles and the Cutaneous Production of Sebum and Use Thereof in Androgenic Alopecia
KR101435228B1 (en) * 2006-07-14 2014-08-28 디에스엠 아이피 어셋츠 비.브이. Compositions and use thereof for the treatment, co-treatment or prevention of inflammatory disorders
EP2445483B1 (en) * 2009-06-25 2017-04-26 McCord, Darlene Topical compositions and methods for wound care

Also Published As

Publication number Publication date
PH12014501044A1 (en) 2015-01-12
WO2014150174A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
ZA202208792B (en) Methods of treating and preventing graft versus host disease
MX2021014709A (en) Methods for increasing red blood cell levels and treating sickle-cell disease.
MX2021010528A (en) Methods and compositions for treating ulcers.
EA201301354A1 (en) SGLT-2 INHIBITORS DESIGNED FOR THE TREATMENT OF METABOLIC DISORDERS IN PATIENTS TREATED BY NEUROLEPTICS
BR112017000301A2 (en) treatment of leukemia with histone deacetylase inhibitors
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
EA201500996A1 (en) THERAPEUTIC APPLICATIONS OF EMAGOGLIFLOSINE
NZ707477A (en) Activin-actrii antagonists and uses for treating bone and other disorders
EA201591674A1 (en) ANTI-TRACT VACCINES AND TREATMENT METHODS WITH THEIR APPLICATION
MX2016007351A (en) Combination therapy for treating cancer.
MX363243B (en) Compositions and methods for treating cancer.
MX2016004678A (en) Methods and compositions for treating cancer.
EA201291031A1 (en) METHOD OF TREATING OBESITY WITH THE USE OF ANTIOXIDANT INFLAMMATION MODULATORS
MX2015016100A (en) Cryopyrin inhibitors for preventing and treating inflammation.
BR112015029386A2 (en) use of eribulin and lenvatinib as combination therapy for cancer treatment
EA201590703A1 (en) MEK INHIBITORS FOR TREATING VIRAL DISEASES
MX2017006015A (en) Apilimod for use in the treatment of renal cancer.
MX2015014599A (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer.
EA201591543A1 (en) COMBINED THERAPIES FOR CANCER TREATMENT WITH THE APPLICATION OF EGFR-TKI MICRORNA AND INHIBITORS
WO2015067755A3 (en) Novel methods and antibodies for treating coagulapathy
EA201591424A1 (en) METHODS OF TREATMENT OF IRON DEFICIENCY WITH SOLUBLE IRON PYROPHOSPHATE
EA032501B9 (en) Methods and compositions for promoting acute wound and chronic wound healing
MX2015012444A (en) Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens.
MX2017006026A (en) Apilimod for use in the treatment of colorectal cancer.